The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events

Autor: Yuko Yasuda, Naoki Shingu, Keisuke Anan, Kazuya Ichikado, Yoshihiko Sakata, Junpei Hisanaga, Tatsuya Nitawaki, Yoshitomo Eguchi, Shigeo Hiroshige, Aiko Nakano, Kodai Kawamura
Rok vydání: 2017
Předmět:
Oncology
Adult
Male
non‐small cell lung cancer
medicine.medical_specialty
Lung Neoplasms
Drug-Related Side Effects and Adverse Reactions
Afatinib
Antineoplastic Agents
03 medical and health sciences
0302 clinical medicine
Gefitinib
tyrosine kinase inhibitor
Internal medicine
Carcinoma
Non-Small-Cell Lung
medicine
Humans
030212 general & internal medicine
Epidermal growth factor receptor
Adverse effect
Lung cancer
Protein Kinase Inhibitors
Aged
Retrospective Studies
Aged
80 and over
Performance status
biology
business.industry
Interstitial lung disease
General Medicine
Original Articles
Middle Aged
medicine.disease
respiratory tract diseases
ErbB Receptors
030220 oncology & carcinogenesis
biology.protein
Female
Original Article
Erlotinib
business
epidermal growth factor receptor
medicine.drug
Zdroj: Asia-Pacific Journal of Clinical Oncology
ISSN: 1743-7563
Popis: Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI because of adverse events provides a benefit. Methods This retrospective study evaluated data from 22 patients with EGFR mutation‐positive NSCLC who received at least two EGFR‐TKIs that were switched because of adverse events (March 2011 to September 2017). Progression‐free survival 2 (PFS2) was defined as the time from starting of the first EGFR‐TKI treatment to disease progression during the second EGFR‐TKI treatment. Results Seventeen patients received gefitinib as the first EGFR‐TKI treatment, while four patients received afatinib and one patient received erlotinib. The median time to failure of the first EGFR‐TKI treatment was 1.6 months. The EGFR‐TKIs were switched because of hepatotoxicity (n = 16), interstitial lung disease (n = 3), and other reasons (n = 3). The median washout period was 1.1 months. Seventeen patients received erlotinib as the second EGFR‐TKI treatment, while three patients received gefitinib and two patients received afatinib. The median PFS for the second EGFR‐TKI treatment was 15.2 months. The median PFS2 was 17.7 months and the median overall survival was 32.8 months. Conclusions Switching EGFR‐TKIs because of adverse events provided a clinical benefit for patients with EGFR mutation‐positive NSCLC. Appropriate judgment regarding switching from one EGFR‐TKI to another may improve the performance status and prognosis of patients with EGFR mutation‐positive NSCLC.
Databáze: OpenAIRE
Externí odkaz: